William Blair acted as the exclusive financial advisor to PhenomeX Inc. (PhenomeX) (Nasdaq: CELL) in connection with its sale to Bruker Corporation (Bruker) (Nasdaq: BRKR). Under terms of the definitive agreement, PhenomeX stockholders will receive $1 per share in cash (roughly $108 million in aggregate equity value), which represents a premium of approximately 150% to the company’s prior closing share price on August 16, 2023 of $0.40 per share. The transaction signed on August 17, 2023 and closed on October 2, 2023.
About the Companies
PhenomeX is a premier functional biology company focused on single cell workflows. Formerly Berkeley Lights, the company rebranded after its acquisition of IsoPlexis in March 2023. It serves customers through products that are designed for diverse applications across a number of important end markets, including antibody therapeutic discovery, cell line development, cell and gene therapy, and AAV workflows.
Bruker is a manufacturer of scientific instruments and diagnostics solutions. The company serves customers across the life sciences, pharmaceutical, and biotechnology industries and has a market cap of about $10 billion.
Learn more about our medical technology investment banking expertise.